Yokohama City Dementia Disease Medical Center

※About lecanemab (rekenbi R infusion)
　On December 20, 2023, Lecanemab, a therapeutic agent that suppresses the progression of Alzheimer's disease, was covered by insurance.
　This is the first approved drug in Japan to control the progress of the disease by working on the causes of Alzheimer's disease.
　・Those with mild cognitive impairment due to Alzheimer's disease and those with mild dementia due to Alzheimer's disease are eligible for treatment.
　・Whether to be administered is to be tested by CDR (clinical dementia scale) and MMSE (neuropsychological test) at the medical institution that administers the drug, as well as other tests.
　　Judgment is made by amyloid PET examination or cerebrospinal fluid examination. In addition, it is necessary to be able to undergo MRI examination (1.5Tesla or higher).
　　Depending on the results of the test, you may not be eligible for treatment if you wish.
　・It is a medicine that goes to the hospital once every two weeks and takes about one hour with infusion.
　For details, please refer to the Ministry of Health, Labour and Welfare website (outside site).

※For citizens who wish to receive lecanemab
　As a medical institution that has a treatment system for lecanemab, the Dementia Disease Medical Center shown in Table above is known as the Medical Center for Dementia Disease (some medical institutions other than the Medical Center for Dementia).
　The handling at each dementia disease medical center and the status of acceptance at that time vary from medical institution to medical institution, so please contact us directly or check the linked page first.
(Reference) Overview of procedures up to lecanemab treatment